

What is claimed is:

1. An agent for inhibiting metastasis of colorectal cancer, wherein the agent inhibits the function of Asef (APC-stimulated guanine nucleotide exchange factor) and/or inhibits the expression of the Asef gene.
2. An agent for inhibiting metastasis of colorectal cancer, wherein the agent inhibits the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.
3. An agent for inhibiting metastasis of colorectal cancer, wherein the agent inhibits the binding of Asef (APC-stimulated guanine nucleotide exchange factor) to the gene product of APC (Adenomatous Polyposis Coli).
4. An agent for inhibiting metastasis of colorectal cancer, wherein the agent inhibits the guanine nucleotide exchange factor activity of Asef (APC-stimulated guanine nucleotide exchange factor).
5. A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the function of Asef (APC-stimulated guanine nucleotide exchange factor) and/or inhibits the expression of the Asef gene.
6. A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.
7. A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the binding of Asef (APC-stimulated guanine nucleotide exchange factor) to the gene product of APC (Adenomatous Polyposis Coli).
8. A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the guanine nucleotide exchange factor activity of Asef (APC-stimulated guanine nucleotide exchange factor).
9. An agent for inhibiting Asef, wherein the agent utilizes RNA interference to inhibit the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.
10. An agent for inhibiting Asef, comprising an oligonucleotide that exhibits an RNA interference effect on the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.

11. An oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing.
12. An oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 2 in the sequence listing.
13. An oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 in the sequence listing.
14. An oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 4 in the sequence listing.
15. The agent according to claim 10, comprising an oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 1 or 3 in the sequence listing.
16. A method for inhibiting Asef, wherein the method utilizes RNA interference on the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.
17. A method for inhibiting Asef, wherein the method comprises utilizing an oligonucleotide exhibiting an RNA interference effect on the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.
18. The method for inhibiting Asef according to claim 17, wherein the method comprises utilizing an oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 1 or 3 in the sequence listing.
19. An agent for inhibiting metastasis of colorectal cancer, comprising the agent according to any one of claims 9, 10 and 15.
20. An agent for inhibiting metastasis of colorectal cancer, comprising an oligonucleotide having the nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 4 in the sequence listing.
21. A method for inhibiting metastasis of colorectal cancer, wherein the method uses the agent according to any one of claims 9, 10 and 15.
22. A method for inhibiting metastasis of colorectal cancer, wherein the method uses an oligonucleotide having the nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 4 in the sequence listing.
23. A pharmaceutical composition, comprising the agent according to any one of claims 1 to

4, 19 and 20, or the agent according to any one of claims 9, 10 and 15.

24. An agent for preventing and/or treating colorectal cancer, comprising the agent according to any one of claims 1 to 4, 19 and 20, or the agent according to any one of claims 9, 10 and 15.

25. A method for preventing and/or treating colorectal cancer, wherein the method uses the agent according to any one of claims 1 to 4, 19 and 20, or the agent according to any one of claims 9, 10 and 15.